|
KPC Pharmaceuticals, Inc. (600422.SS) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
KPC Pharmaceuticals, Inc. (600422.SS) Bundle
As an investor or analyst, this DCF Calculator for KPC Pharmaceuticals, Inc. (600422SS) serves as your essential tool for accurate valuation. Loaded with real data from KPC Pharmaceuticals, you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,120.0 | 7,717.1 | 8,253.5 | 8,282.1 | 7,703.1 | 7,613.5 | 7,524.9 | 7,437.3 | 7,350.8 | 7,265.2 |
| Revenue Growth, % | 0 | -4.96 | 6.95 | 0.34568 | -6.99 | -1.16 | -1.16 | -1.16 | -1.16 | -1.16 |
| EBITDA | 727.4 | 757.0 | 870.9 | 726.8 | 801.8 | 738.6 | 730.0 | 721.5 | 713.1 | 704.8 |
| EBITDA, % | 8.96 | 9.81 | 10.55 | 8.78 | 10.41 | 9.7 | 9.7 | 9.7 | 9.7 | 9.7 |
| Depreciation | 136.0 | 172.0 | 197.5 | 243.6 | 213.6 | 182.9 | 180.8 | 178.7 | 176.6 | 174.5 |
| Depreciation, % | 1.67 | 2.23 | 2.39 | 2.94 | 2.77 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 |
| EBIT | 591.4 | 585.0 | 673.4 | 483.2 | 588.2 | 555.7 | 549.2 | 542.8 | 536.5 | 530.3 |
| EBIT, % | 7.28 | 7.58 | 8.16 | 5.83 | 7.64 | 7.3 | 7.3 | 7.3 | 7.3 | 7.3 |
| Total Cash | 1,482.0 | 1,807.9 | 1,734.8 | 1,977.8 | 2,096.8 | 1,732.8 | 1,712.6 | 1,692.7 | 1,673.0 | 1,653.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,604.4 | 1,551.4 | 2,010.9 | 2,624.6 | 2,894.7 | 2,032.7 | 2,009.0 | 1,985.7 | 1,962.5 | 1,939.7 |
| Account Receivables, % | 19.76 | 20.1 | 24.36 | 31.69 | 37.58 | 26.7 | 26.7 | 26.7 | 26.7 | 26.7 |
| Inventories | 1,431.3 | 1,717.6 | 1,883.6 | 1,680.7 | 1,688.2 | 1,597.5 | 1,578.9 | 1,560.6 | 1,542.4 | 1,524.5 |
| Inventories, % | 17.63 | 22.26 | 22.82 | 20.29 | 21.92 | 20.98 | 20.98 | 20.98 | 20.98 | 20.98 |
| Accounts Payable | 749.4 | 823.7 | 1,238.5 | 977.1 | 932.7 | 895.6 | 885.1 | 874.8 | 864.7 | 854.6 |
| Accounts Payable, % | 9.23 | 10.67 | 15.01 | 11.8 | 12.11 | 11.76 | 11.76 | 11.76 | 11.76 | 11.76 |
| Capital Expenditure | -347.3 | -158.7 | -236.2 | -101.7 | -65.5 | -171.7 | -169.7 | -167.7 | -165.8 | -163.8 |
| Capital Expenditure, % | -4.28 | -2.06 | -2.86 | -1.23 | -0.85007 | -2.25 | -2.25 | -2.25 | -2.25 | -2.25 |
| Tax Rate, % | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 | 21.1 |
| EBITAT | 493.5 | 494.5 | 541.6 | 387.9 | 464.1 | 453.0 | 447.7 | 442.5 | 437.3 | 432.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,004.2 | 348.8 | 292.2 | -142.4 | 290.1 | 1,379.8 | 490.6 | 484.9 | 479.3 | 473.7 |
| WACC, % | 4.98 | 4.99 | 4.98 | 4.97 | 4.97 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,944.8 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 490 | |||||||||
| Terminal Value | 33,172 | |||||||||
| Present Terminal Value | 26,019 | |||||||||
| Enterprise Value | 28,963 | |||||||||
| Net Debt | -322 | |||||||||
| Equity Value | 29,285 | |||||||||
| Diluted Shares Outstanding, MM | 754 | |||||||||
| Equity Value Per Share | 38.86 |
What You Will Receive
- Genuine KPC Financial Data: Access to both historical and projected data for precise valuation.
- Customizable Parameters: Adjust inputs such as WACC, tax rates, revenue growth, and capital expenditures.
- Automated Calculations: Features dynamic calculations for intrinsic value and NPV.
- Scenario Analysis: Evaluate various scenarios to assess KPC Pharmaceuticals' (600422SS) future performance.
- User-Friendly Design: Designed for professionals while remaining accessible to newcomers.
Key Features
- Pre-Loaded Data: KPC Pharmaceuticals’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: Watch KPC Pharmaceuticals’ intrinsic value update in real time.
- Clear Visual Outputs: Dashboard charts illustrate valuation results and essential metrics.
- Built for Accuracy: A professional-grade tool designed for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file featuring KPC Pharmaceuticals, Inc.'s (600422SS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly analyze the results.
- Make Decisions: Utilize the valuation findings to inform your investment strategy.
Why Opt for This Calculator?
- Precise Information: Utilize real KPC Pharmaceuticals financial data for trustworthy valuation outcomes.
- Flexible Options: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Efficiency Boost: Built-in calculations help you avoid starting from the ground up.
- Expert-Level Tool: Crafted for investors, analysts, and consultants alike.
- Easy to Navigate: User-friendly design and clear, step-by-step guidance ensure accessibility for everyone.
Who Can Benefit from This Product?
- Investors: Evaluate KPC Pharmaceuticals, Inc.'s (600422SS) valuation before making stock transactions.
- CFOs and Financial Analysts: Optimize valuation workflows and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established companies like KPC Pharmaceuticals, Inc. (600422SS).
- Consultants: Create comprehensive valuation reports for your clients.
- Students and Educators: Utilize real-world case studies to practice and teach valuation methodologies.
Contents of the Template
- Preloaded KPC Data: Historical and projected financial metrics, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade worksheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for modifying revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financials for in-depth analysis.
- Key Ratios: Ratios for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.